Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
NovaBiotics Ltd logo — Developing first-in-class solutions for unmet health and per...

NovaBiotics Ltd

Developing first-in-class solutions for unmet health and personal care needs

Founded 2004 United Kingdom Aberdeen, United Kingdom 14 employees Grant Total: $11.90M Biotechnology, Health Care

General Information

Company Name NovaBiotics Ltd
Founded Year 2004
Location United Kingdom Aberdeen, United Kingdom
Employees 14
Industries Biotechnology, Health Care
Funding Stage Grant
Social

BounceWatch is an independent company data service, not affiliated with NovaBiotics Ltd. To contact NovaBiotics Ltd, visit novabiotics.co.uk.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does NovaBiotics Ltd compare?

A PDF of NovaBiotics Ltd and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting NovaBiotics Ltd soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About NovaBiotics Ltd

NovaBiotics Ltd is a clinical-stage biotechnology company that aims to address medically unmet, life-threatening, and life-limiting diseases through novel, immune-based therapies. The company's pipeline includes clinical stage antimicrobials derived from NovaBiotics' proprietary anti-infective peptide platform, as well as the "mini biologic" antibacterial-mucolytic compound, Lynovex®. One of their key developments is NP213 (Novexatin®), a first-in-class antifungal agent designed as a topical treatment for fungal nail infections (onychomycosis). They expect to launch this product as a 1x daily, 28-day brush-on-treatment in 2022, addressing a condition that affects over 10% of the global population. Moreover, NovaBiotics’ NM001 (Lynovex®) offers an orphan drug treatment for cystic fibrosis, presenting a unique dual antibacterial-mucoactive mode of action. The company is currently evaluating it in Phase IIa clinical trials and formulating it for inhalation to enable more targeted delivery. The company also maintains a strong preclinical stage pipeline with promising candidates, such as NP339 (Novamycin®) and NP432 (Novarifyn®). A standout feature of NovaBiotics is its robust IP portfolio of granted and pending patents, providing a solid foundation for its innovations. The company, founded in 2004 and headquartered in the United Kingdom, has raised approximately £25 million in equity investment since its inception. One of their notable recent investments includes a £1.00M grant from Innovate UK on 16 October 2020. With its innovative approach and significant funding, NovaBiotics presents a compelling prospect in the biotechnology and healthcare industries.

Business keywords: drug development, immunology, antimicrobials, clinical-stage, infectious disease, biologic compounds, cystic fibrosis, anti-infective peptides, fungal nail infections, onchomycosis treatment, preclinical drug candidates, IP portfolio, equity investment, medical innovation

Funding Rounds & Investors (5)

View All
Funding Stage Amount Investors Lead Investors Date
Grant £1.00M 1
Innovate UK
Innovate UK
16 Oct 2020
Grant £1.80M -
20 Feb 2019
Venture Round £3.00M 2
Woodford Patient Capital Trust
Woodford Patient Capital Trust, Grampian Biopartners
03 Mar 2016
Venture Round £5.00M 1
Woodford Patient Capital Trust
Woodford Patient Capital Trust
19 Jan 2015
Angel Round £1.10M 1
Aurora Private Equity
Aurora Private Equity
01 Jun 2009

NovaBiotics Ltd Alternatives & Competitors

View All Alternatives
NovaBiotics Ltd vs
Clarametyx Biosciences
Clarametyx Biosciences United States

Targeting biofilms to treat chronic respiratory disease

Series A
23 employees
Biotechnology, Health Care
NovaBiotics Ltd vs
OCEAN BIOMEDICAL
OCEAN BIOMEDICAL United States

Empowering great medical science.

Post-IPO Debt
12 employees
Biotechnology, Health Care
NovaBiotics Ltd vs
Armata Pharmaceuticals, Inc.
Armata Pharmaceuticals, Inc. United States

PURPOSEFUL. PRECISE. POWERFUL.

Post-IPO Debt
71 employees
Biotechnology, Health Care
Also compare with: NovaBiotics Ltd vs Mediar Therapeutics Mediar Therapeutics View all alternatives

FAQ About NovaBiotics Ltd

Developing first-in-class solutions for unmet health and personal care needs
NovaBiotics Ltd was founded in 2004.
NovaBiotics Ltd is headquartered in Aberdeen, United Kingdom.
NovaBiotics Ltd operates in Biotechnology and Health Care. Its work centres on drug development, immunology, antimicrobials and clinical-stage.
NovaBiotics Ltd has approximately 14 employees.
NovaBiotics Ltd has completed 5 funding rounds, raising a total of $11.90M. The latest funding stage is Grant.
Top alternatives and competitors to NovaBiotics Ltd include Clarametyx Biosciences, OCEAN BIOMEDICAL, Armata Pharmaceuticals, Inc., Mediar Therapeutics, Tolerx, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
NovaBiotics Ltd and Clarametyx Biosciences are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for NovaBiotics Ltd, https://bouncewatch.com/company/novabiotics-ltd, updated 13 November 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout